gallic acid has been researched along with transferrin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista, AA; Cominetti, MR; Graminha, AE; Honorato, J; Luna-Dulcey, L; Menezes, ACS; Naves, MA; Vegas, LC | 1 |
| Batista, AA; Cominetti, MR; Correa, RS; Graminha, AE; Honorato, J; Menezes, ACS | 1 |
2 other study(ies) available for gallic acid and transferrin
| Article | Year |
|---|---|
Transport of the Ruthenium Complex [Ru(GA)(dppe)
Topics: Antineoplastic Agents; Apoptosis; Biological Transport, Active; Cell Line, Tumor; Cell Movement; Cisplatin; Coordination Complexes; DNA, Neoplasm; Female; Gallic Acid; Humans; Ligands; Molecular Structure; Neoplasm Invasiveness; Receptors, Transferrin; Ruthenium; Serum Albumin, Human; Transferrin; Triple Negative Breast Neoplasms | 2019 |
A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells.
Topics: Actin Cytoskeleton; Animals; Antineoplastic Agents; Apoproteins; Biphenyl Compounds; Cell Adhesion; Cell Line; Cell Movement; Cell Survival; Coordination Complexes; Gallic Acid; Humans; Mice; Picrates; Pyridines; Ruthenium; Serum Albumin, Bovine; Transferrin; Triple Negative Breast Neoplasms | 2021 |